97284 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL Framework region [FR]
M-CSF Antibody compositions Having Reduced Levels of Endotoxin
#2102Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies
#2103CA6 antigen-specific cytotoxic conjugate and methods of using the same
#2104ANTIBODY COMPOSITIONS AND METHODS
#2105Construction of diverse synthetic peptide and polypeptide libraries
#2106Humanized PAI-1 antibodies
#2107Anti-Notch1 NRR antibodies
#2108ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES FOR TREATMENT OF DEPRESSION AND RELATED CONDITIONS
#2109C3b antibodies and methods for the prevention and treatment of complement-associated disorders
#2110METHODS OF MODIFYING ANTIBODIES, AND MODIFIED ANTIBODIES WITH IMPROVED FUNCTIONAL PROPERTIES
#2111IL-17 receptor A antigen binding proteins
#2112Humanized antibodies that recognize beta amyloid peptide
#2113Humanized anti-CD79b antibodies and immunoconjugates and methods of use
#2114METHODS AND COMPOSITIONS FOR TREATING AND MONITORING TREATMENT OF IL-13-ASSOCIATED DISORDERS
#2115Deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
#2116Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#2117Treatment with Anti-VEGF Antibodies
#2118Anti-CD79B antibodies and immunoconjugates and methods of use
#2119Sequence based engineering and optimization of single chain antibodies
#2120Multispecfic deimmunized CD3-binders
#2121Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#2122Antigen binding molecules with increased Fc receptor binding affinity and effector function
#2123TREATMENT WITH ANTI-VEGF ANTIBODIES
#2124TREATMENT WITH ANTI-VEGF ANTIBODIES
#2125Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
#2126Device for detecting molecules, method for detecting molecules
#2127Anti-IL2 antibodies
#2128Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
#2129Effect of Bst2 on inflammation
#2130Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
#2131TREATMENT WITH ANTI-VEGF ANTIBODIES
#2132TREATMENT WITH ANTI-VEGF ANTIBODIES
#2133Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#2134Anti-αβantibodies and uses thereof
#2135HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE
#2136Treatment With Anti-VEGF Antibodies
#2137TREATMENT WITH ANTI-VEGF ANTIBODIES
#2138OPTIMIZED ANTIBODIES THAT TARGET CD19
#2139Irta-4 Antibodies and Their Uses
#2140TREATMENT WITH ANTI-VEGF ANTIBODIES
#2141TREATMENT WITH ANTI-VEGF ANTIBODIES
#2142Immunoglobulin Variants Outside the Fc Region
#2143TREATMENT WITH ANTI-VEGF ANTIBODIES
#2144Reducing the immunogenicity of anti-CD20 antibodies by framework patching
#2145PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#2146Prevention and treatment of amyloidogenic disease
#2147ANTI-VEGF ANTIBODIES
#2148Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
#2149Humanized antibodies that recognize beta amyloid peptide
#2150Polynucleotides encoding IL-17 receptor A antigen binding proteins
#2151Methods of treating psoriasis using IL-17 Receptor A antibodies
#2152Human anti-CD100 antibodies
#2153COMPOUNDS
#2154Anti-human IL-6 antibodies
#2155Antibodies and methods for making and using them
#2156ANTI-VEGF ANTIBODIES
#2157Framework patched anti-CD20 antibody
#2158Modified human IGF-IR antibodies
#2159Methods of generating variant proteins with increased host string content
#2160TREATMENT WITH ANTI-VEGF ANTIBODIES
#2161TREATMENT WITH ANTI-VEGF ANTIBODIES
#2162Compositions and methods of tolerizing a primate to an antigen
#2163Method for improving antibody
#2164Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#2165Anti-Notch3 antibodies
#2166Anti-tumor agent
#2167Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
#2168Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#2169Anti-ErbB2 antibodies
#2170Specific binding members for NGF
#2171PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#2172IL-17 and IL-23 antagonists and methods of using the same
#2173Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#2174Humanized anti-CEA T84.66 antibody and uses thereof
#2175Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
#2176Humanized Antibody
#2177Antibodies Directed to AlphaVBeta6 and Uses Thereof
#2178Humanized antibodies that recognize beta amyloid peptide
#2179EphA2 BiTE molecules and uses thereof
#2180Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
#2181Treatment of cancer with a novel anti-IL13 monoclonal antibody
#2182REDUCING IMUNOGENICITIES OF IMMUNOGLOBULINS BY FRAMEWORK-PATCHING
#2183BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS
#2184Humanised anti-interleukin-18 antibody
#2185Antibodies that bind interleukin-4 receptor
#2186Treatment of tumors expressing mutant EGF receptors
#2187Antibodies to TGF-beta
#2188Treatment with anti-VEGF antibodies
#2189Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#2190Protein engineering with analogous contact environments
#2191Anti-VEGF antibodies
#2192Antibodies and methods for generating genetically altered antibodies with high affinity
#2193Immunoglobulins devoid of light chains
#2194Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#2195Insulin-like growth factor antibodies and uses thereof
#2196ANTI-VEGF ANTIBODIES
#2197Chimeric, human and humanized anti-granulocyte antibodies and methods of use
#2198TREATMENT WITH ANTI-VEGF ANTIBODIES
#2199TREATMENT WITH ANTI-VEGF ANTIBODIES
#2200Anti-CD19 antibodies with reduced immunogenicity
#2201TREATMENT WITH ANTI-VEGF ANTIBODIES
#2202TREATMENT WITH ANTI-VEGF ANTIBODIES
#2203Antibodies to TGF-BETA
#2204Anti-α2 integrin antibodies and their uses
#2205Anti-CD26 antibodies and methods of use thereof
#2206Antibody reactive with human toll like receptor 3
#2207Ligand
#2208Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#2209Immunoglobulins devoid of light chains
#2210TREATMENT WITH ANTI-VEGF ANTIBODIES
#2211TREATMENT WITH ANTI-VEGF ANTIBODIES
#2212Modified antigen binding molecules with altered cell signaling activity
#2213TREATMENT WITH ANTI-VEGF ANTIBODIES
#2214Antibody compositions and methods
#2215Antibodies against interleukin-1β
#2216Anti-VEGF antibodies
#2217Anti-interferon-α antibodies
#2218Biological products
#2219CD37 immunotherapeutics and uses thereof
#2220ANTI-VEGF ANTIBODIES
#2221Anti-interferon-α antibodies
#2222CA6 antigen-specific cytotoxic conjugate and methods of using the same
#2223Generation and selection of protein library in silico
#2224TREATMENT WITH ANTI-VEGF ANTIBODIES
#2225TREATMENT WITH ANTI-VEGF ANTIBODIES
#2226TREATMENT WITH ANTI-VEGF ANTIBODIES
#2227Biosynthetic binding proteins for immuno-targeting
#2228TREATMENT WITH ANTI-VEGF ANTIBODIES
#2229TREATMENT WITH ANTI-VEGF ANTIBODIES
#2230Method for screening a library of VHH polypeptides
#2231Method of humanizing antibodies by matching canonical structure types CDRs
#2232Pegylated immunoglobulin variable region polypeptides
#2233Humanized antibodies that recognize beta amyloid peptide
#2234GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
#2235Anti-il-6 antibodies, compositions, methods and uses
#2236Antibodies to TGF-β
#2237High affinity anti-human IgE antibodies
#2238Anti-CD19 antibodies and uses in oncology
#2239Anti-ghrelin antibodies
#2240Processes and products with modified antibodies of human milk fat globule specificity
#2241Agonist antibodies
#2242Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
#2243Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
#2244Biosynthetic binding proteins for immuno-targeting
#2245Fully human monoclonal antibodies to IL-13
#2246Immunoglobulins devoid of light chains
#2247Immunoglobulin variable region cassette exchange
#2248Device for detecting molecules, method for detecting molecules
#2249Immunoglobulins devoid of light chains
#2250Methods of preventing and treating RSV infections and related conditions
#2251Toll like receptor 3 antagonists, methods and uses
#2252Proteins capable of binding to female sex hormones and process for producing the same
#2253Humanized anti-VLA4 immunoglobulins
#2254Ligand
#2255Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response
#2256Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
#2257Ligand
#2258Engineered antibody fragment that irreversibly binds an antigen
#2259Methods of use for antibodies against parathyroid hormone
#2260Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
#2261Method of inhibition of vascular development using an antibody
#2262Humanized antibodies that sequester abeta peptide
#2263Compositions and methods for diagnosing and treating an inflammation
#2264Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
#2265Prevention and treatment of amyloidogenic disease
#2266Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
#2267Immunoglobulin variants and uses thereof
#2268Prevention and treatment of amyloidogenic disease
#2269Immunoglobulin variants and uses thereof
#2270Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
#2271Methods of generating variant antibodies with increased host string content
#2272Protein engineering with analogous contact environments
#2273Human monoclonal antibodies against protective antigen
#2274Antibodies against human IL-12
#2275Reagents and methods useful for detecting diseases of the gastrointestinal tract
#2276Variable domain library and uses
#2277Super humanized antibodies
#2278Antibody specificity transfer using minimal essential binding determinants
#2279Prevention and treatment of amyloidogenic disease
#2280Humanized antibodies that recognize beta amyloid peptide
#2281Immunoglobulin variants outside the Fc region
#2282Humanized anti-CEA T84.66 antibody and uses thereof
#2283Humanized antibody
#2284Method for displaying loops from immunoglobulin domains in different contexts
#2285Monoclonal antibodies with reduced immunogenicity
#2286Agonist antibodies
#2287Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
#2288Prevention and treatment of amyloidogenic disease
#2289Prevention and treatment of amyloidogenic disease
#2290IP-10 antibodies and their uses
#2291Prevention and treatment of amyloidogenic disease
#2292Treatment with anti-VEGF antibodies
#2293Identification of novel IgE epitopes
#2294Prevention and treatment of amyloidogenic disease
#2295Prevention and treatment of amyloidogenic disease
#2296CA6 antigen-specific cytotoxic conjugate and methods of using the same
#2297Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
#2298Humanized antibodies that recognize beta amyloid peptide
#2299Antibodies that bind interleukin-4 receptor
#2300Synthetic antibody phage libraries
#2301Interleukin-1 beta antibodies
#2302Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
#2303Anti-interleukin-1 beta analogs
#2304Modified human IGF-IR antibodies
#2305Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
#2306Method and compositions for immunization with the V antigen
#2307Biosynthetic binding proteins for immuno-targeting
#2308Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
#2309Prevention and treatment of amyloidogenic disease
#2310Immunoglobulin having particular framework scaffold and methods of making and using
#2311Prevention and treatment of amyloidogenic disease
#2312Methods for humanizing rabbit monoclonal antibodies
#2313Humanised antibodies and uses thereof
#2314Reducing immunogenicities of immunoglobulins by framework-patching
#2315Prevention and treatment of amyloidogenic disease
#2316Prevention and treatment of amyloidogenic disease
#2317Prevention and treatment of amyloidogenic disease
#2318Prevention and treatment of amyloidogenic disease
#2319Antibodies against drugs of abuse
#2320Humanized antibodies that recognize beta amyloid peptide
#2321Anti-CD79B protein monoclonal antibody, products containing the same, and uses thereof
#2322Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
#2323Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof
#2324Coronavirus neutralizing humanized antibodies and uses thereof
#2325Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
#2326Vista antigen-binding molecules